title: Role of Neprilysin Inhibitors in Heart Failure.
abstract: Heart failure (HF) is a complex multifactorial medical condition that should be addressed according to its complexity and diversity. Currently, there is a medical arsenal available for the management of HF, but despite the advance in medical resources, its prevalence and social and financial impacts are still worrisome for the medical community and society. Among the numerous therapeutic options for the treatment of HF, neprilysin inhibitors have changed the perspective of the approach to titrate patients who suffer from this condition because neprilysin plays a role in the degradation of natriuretic peptides and various other vasoactive compounds that are crucial to counteract the devastating pathophysiology of HF. The purpose of this review was to analyze the role of neprilysin inhibitors in HF, focusing on newer therapy such as LCZ696 and studies that sustain its potential benefits in this medical entity.
authors.affiliation: 1University of Cuenca, Faculty of Medical Sciences, Medical School, Cuenca, Ecuador; and 2Department of Cardiology, Rosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, IL.
authors.forename: Juan P
authors.initials: JP
authors.lastname: Salazar Adum
authors.forename: Rohit
authors.initials: R
authors.lastname: Arora
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000379:methods; D004656:Enalapril / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015995:Prevalence; D065667:Renal Elimination; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D004656:Enalapril; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination